Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Unity Biotechnology's Enterprise Value is $2.71 Mil.
Unity Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-27.09 Mil. Therefore, Unity Biotechnology's EV-to-EBIT ratio for today is -0.10.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Unity Biotechnology's Enterprise Value is $2.71 Mil.
Unity Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-26.27 Mil. Therefore, Unity Biotechnology's EV-to-EBITDA ratio for today is -0.10.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Unity Biotechnology (OTCPK:UNBX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
Unity Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.09 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
Unity Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.27 Mil.
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
Unity Biotechnology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
Unity Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.04 Mil.
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
Unity Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unity Biotechnology Enterprise Value Related Terms
Unity Biotechnology Enterprise Value Historical Data
* Premium members only.
The historical data trend for Unity Biotechnology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UNBX vs ADTX, HEPA, EVFM: Enterprise Value Comparison
For the Biotechnology subindustry, Unity Biotechnology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unity Biotechnology Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Unity Biotechnology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Unity Biotechnology's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unity Biotechnology (UNBX) has a Enterprise Value of $2.71 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Enterprise Value too high?
Unity Biotechnology's current Enterprise Value is $2.71 Mil.
How does Unity Biotechnology's Enterprise Value compare to ADTX and HEPA?
Unity Biotechnology's Enterprise Value of $2.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Enterprise Value is $2.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Enterprise Value of $2.71 Mil. The current Enterprise Value is $2.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Enterprise Value is $2.71 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UNBX has been successfully added to your 